ALK-negative anaplastic large cell lymphoma
MONDO:0017603ALK-negative anaplastic large cell lymphoma (ALK- ALCL) is a type of ALCL, a rare and aggressive peripheral T-cell non-Hodgkin lymphoma affecting lymph nodes and extranodal sites, which is characterized by the lack of expression of a protein called anaplastic lymphoma kinase (ALK).
Also known as: ALCL, ALK-, ALK- ALCL, ALK- anaplastic large cell lymphoma, ALK-negative anaplastic large cell lymphoma, anaplastic large cell lymphoma, ALK-negative
1967 clinical trials for this condition and its sub-types, 20 tagged with ALK-negative anaplastic large cell lymphoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →-
Can a smart immune cell with a kill switch beat tough lymphomas?
Cure Not yet recruitingThis Phase 1 trial tests a new type of cell therapy for people with relapsed or refractory CD30-positive lymphomas, including Hodgkin lymphoma and certain non-Hodgkin lymphomas. The treatment uses a patient's own immune cells that are genetically engineered to recognize and attac…
Phase 1 • Sponsor: The Methodist Hospital Research Institute • Aim: Cure
Last updated Jul 29, 2026 00:00 UTC
-
Supercharged immune cells take on tough T-Cell cancers
Disease control Not yet recruitingThis Phase 2 trial tests a new treatment for aggressive T-cell blood cancers. Patients receive specially engineered natural killer (NK) cells from donated cord blood, along with chemotherapy, to try to keep the cancer in remission. The study will enroll 70 adults aged 18-80 whose…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 22, 2026 00:00 UTC
-
New chemo cocktail aims to treat rare lymphoma without heart damage
Disease control Not yet recruitingThis phase 2 trial tests a new chemotherapy combination called CAOP for elderly patients (65+) with untreated peripheral T-cell lymphoma, a rare blood cancer. The standard treatment often causes heart damage, but this regimen replaces the heart-toxic drug with a safer one. The st…
Phase 2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC